DGAP-News

NEOVACS SCIENTIFIC ADVISORY BOARD ENDORSES COMPANY'S UPDATED IFNα-KINOID DEVELOPMENT PLAN

DGAP-News: Neovacs S.A. / Key word(s): Miscellaneous
NEOVACS SCIENTIFIC ADVISORY BOARD ENDORSES COMPANY'S UPDATED
IFNα-KINOID DEVELOPMENT PLAN

04.03.2015 / 08:00

---------------------------------------------------------------------

PRESS RELEASE

NEOVACS SCIENTIFIC ADVISORY BOARD ENDORSES COMPANY'S UPDATED IFNα-KINOID
DEVELOPMENT PLAN

- IFNα-Kinoid program to target Systemic Lupus Erythematosus (SLE) as
first indication

- Important pipeline extension to dermatomyositis, an orphan condition
linked to IFNα

- SAB concludes final review of TNF-Kinoid Phase IIb data


Paris, March 4, 2015 - NEOVACS(Alternext Paris : ALNEV), a leader in
active immunotherapies for the treatment of autoimmune diseases, today
provided details about its updated clinical path forward, focusing on
IFNα-Kinoid. The Company's decision to focus on IFNα-Kinoid was based on
conclusions from its international Scientific Advisory Board (SAB) meeting,
which took place in New York on February 12, 2015.

Neovacs' international SAB, comprised of leaders in immune therapy, chronic
inflammatory and autoimmune diseases, reviewed the Company's clinical
results and development plans, and made the following recommendations to
the management.

Moving forward with IFNα-Kinoid in Systemic Lupus Erythematosus (SLE)

Neovacs' SAB reviewed the pre-clinical trials of IFNα-Kinoid, conducted
from 2005-2009, as well as the results of the Phase I/IIa trial on 28
patients which concluded in 2011 (Lauwerys et al., Arthritis & Rheumatism,
2013). Study results demonstrated:

- The Kinoid was well tolerated by patients;

- Patients experienced a strong immune response with a significantly
higher production of binding antibodies than that observed with the TNF
Kinoid in humans;

- Significant production of antibodies with strong neutralizing
capacity.

The SAB further reviewed a comparative analysis conducted by Neovacs in
2013, evaluating IFNα-Kinoid against ann anti-IFNα monoclonal antibody
under clinical development. In this comparative trial, Neovacs' IFNα-Kinoid
achieved strong neutralization of all 13 subtypes of IFNα, while the
monoclonal antibody used in the study strongly neutralized only two of
these subtypes.*

Based on these findings, SAB members expressed full support for the
forthcoming Phase IIb trial of IFNα-Kinoid in approximatively 160 patients